TNXP - Tonix Pharmaceuticals Holding Corp.
| Previous Close | 2.9400 |
| Open | 2.9000 |
| Bid | 2.77 x 900 |
| Ask | 2.79 x 800 |
| Day's Range | 2.6400 - 2.9300 |
| 52 Week Range | 0.3600 - 9.6000 |
| Volume | 333,395 |
| Avg. Volume | 1,607,130 |
| Market Cap | 4.313M |
| Beta (3Y Monthly) | 0.36 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -28.52 |
| Earnings Date | Nov 5, 2018 - Nov 9, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.13 |
- InvestorPlace•3 days ago
Nano Cap News: Why Tonix Pharmaceuticals (TNXP) Stock Is Moving Today
Tonix Pharmaceuticals (NASDAQ:TNXP) says that it is holding a new public offering that has a total value of $15 billion. The company notes that it plans to use funds from this public offering to fuel a new Phase 3 study for TNX-102 SL, which is its lead product candidate. According to Tonix Pharmaceuticals, it will be selling Class A and Class B shares of its stock during the public offering.
- GlobeNewswire•3 days ago
Tonix Pharmaceuticals Prices $15,000,000 Public Offering
Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense, announced today the pricing of an underwritten public offering with expected total gross proceeds of $15,000,000 before deducting underwriting discounts, commissions and other offering expenses payable by the Company. The Company expects to use the net proceeds from this offering to help fund a new Phase 3 study using a modified trial design for its lead product candidate, TNX-102 SL, and for working capital and other general corporate purposes. The securities offered by the Company consist of (i) Class A Units each consisting of one share of Common Stock and one Warrant to purchase one share of Common Stock at a price of $3.50 per Class A Unit, and (ii) Class B Units each consisting of one share of Series A Convertible Preferred Stock, with a stated value of $1,000 per share, and convertible into 286 shares of Common Stock per share of Series A Preferred Stock, and Warrants to purchase 286 shares of Common Stock, at a combined price of $1,000 per Class B Unit.
- ACCESSWIRE•7 days ago
Tonix Pharmaceuticals Prepares for Phase III Trial for Tonmya, Analysts Review and Target
NEW YORK, NY / ACCESSWIRE / December 3, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Tonix Pharmaceuticals Holding Corp. (TNXP), a clinical-stage biopharmaceutical company focused on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense through potential medical counter-measures. Tonix is developing Tonmya, which has been conditionally accepted by the U.S. Food and Drug Administration (FDA) as the proposed trade name for TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for the treatment of PTSD. New composition of matter patent was issued in November which expands the Company's intellectual property protection for Tonmya, or TNX-102 SL, in the U.S. The patent is part of an expanding portfolio of patents and patent applications and other intellectual property addressing the formulation, manufacturing, and uses of Tonmya, or TNX-102 SL, for a variety of indications including posttraumatic stress disorder, agitation in Alzheimer's disease and fibromyalgia.
- GlobeNewswire•11 days ago
Tonix Pharmaceuticals Announces Additional Details of the New Phase 3 Study of Tonmya® for PTSD, Following Receipt of FDA Minutes
Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company), today announced that it has received the official minutes from the October 29th Breakthrough Therapy Type B Clinical Guidance meeting with the U.S. Food and Drug Administration (FDA). The minutes are consistent with the preliminary guidance the Company received at the meeting and confirm FDA’s acceptance of the new Phase 3 “RECOVERY” study design. As previously communicated, the Company plans to start the RECOVERY trial for the treatment of posttraumatic stress disorder (PTSD) in the first quarter of 2019.
- GlobeNewswire•13 days ago
Tonix Pharmaceuticals Announces 1-for-10 Reverse Stock Split
Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix), a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense, announced today that it will effect a 1-for-10 reverse stock split of its outstanding common stock. The reverse stock split was previously approved by the Board of Directors of Tonix in accordance with Nevada law, under which no stockholder approval is required, and is intended to increase the per share trading price of Tonix’s common stock to satisfy the $1.00 minimum bid price requirement for continued listing on The NASDAQ Global Market (Rule 5450(a)(1)). Tonix’s common stock will continue to trade on the NASDAQ Global Market under the symbol “TNXP” and under a new CUSIP number, 890260508.
- GlobeNewswire•19 days ago
Analysis: Positioning to Benefit within The ONE Group Hospitality, Biofrontera AG Sponsored ADR, Aridis Pharmaceuticals, Universal Logistics, Tonix Pharmaceuticals Holding, and AVROBIO — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Zacks Small Cap Research•21 days ago
TNXP: Ready to Initiate Phase 3 Trial of TNX-102 SL in PTSD in 1Q19…
On October 31, 2018, Tonix Pharmaceuticals Holding Corp. (TNXP) announced that the company will be initiating a new Phase 3 trial for TNX-102 SL in posttraumatic stress disorder (PTSD) in the first quarter of 2019. 1) The primary endpoint will be the change from baseline in CAPS-5 score at 4 weeks. 2) Inclusion will be limited to individuals with PTSD who experienced their trauma within the past nine years, while the HONOR study included individuals who experienced a trauma from 2001 or later.
- Associated Press•last month
Tonix: 3Q Earnings Snapshot
The New York-based company said it had a loss of 57 cents per share. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss ...
- GlobeNewswire•last month
Tonix Pharmaceuticals Announces New Patent Coverage Protecting Tonmya®
Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company) today announced that the U.S. Patent and Trademark Office ("USPTO") issued U.S. Patent No. 10,117,936 to the Company on November 6, 2018. This patent, “Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride,” includes 34 claims directed to pharmaceutical compositions of eutectics of cyclobenzaprine hydrochloride and mannitol and methods of making those compositions. This patent is expected to provide Tonix with U.S. market exclusivity until 2034. The patent is part of an expanding portfolio of patents and patent applications and other intellectual property addressing the formulation, manufacturing, and uses of Tonmya*, or TNX-102 SL, for a variety of indications including posttraumatic stress disorder, agitation in Alzheimer’s disease, and fibromyalgia.
- GlobeNewswire•last month
Tonix Pharmaceuticals Presented Results and Retrospective Analyses of Phase 3 P301 “HONOR” Study in Poster Presentation at CNS Summit 2018
Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company) presented a poster at CNS Summit 2018 held November 1-4, 2018, in Boca Raton, Fla. A poster, entitled “Time Since Trauma in PTSD: Phase 3 Multi-Center, Double-Blind, Placebo-Controlled Trial of TNX-102 SL*, a Sublingual Formulation of Cyclobenzaprine, in Military-Related PTSD (Study TNX-CY-P301)” includes results and retrospective analyses from the Phase 3 P301 study (“HONOR”). The poster presentation reports that a retrospective analysis revealed a treatment effect in participants who experienced trauma less than or equal to nine years prior to screening (approximately 50% of the modified intent-to-treat population). For this subgroup, the p-value of the primary endpoint at Week 12, using mixed model repeated measures with multiple imputation (MMRM with MI), was 0.039.
- ACCESSWIRE•last month
Today’s Research Reports on Stocks to Watch: Tonix Pharmaceuticals and ACADIA Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / November 1, 2018 / Shares of Tonix Pharmaceuticals were flying higher in Wednesday’s session on news that the company plans to start a new Phase 3 trial of Tonmya, a drug formulation ...
- GlobeNewswire•last month
Tonix Pharmaceuticals to Present at BIO-Europe International Partnering Conference
NEW YORK, Nov. 01, 2018 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix,.
- ACCESSWIRE•last month
Healthcare Market Growth Could Fuel These Stocks
CORAL GABLES, FL / ACCESSWIRE / October 31,2018 / The bounce back for healthcare stocks started in May 2018 but faced some selling pressure in more recent trading session as market volatility grew. As far as healthcare stocks are concerned, 2018 and most likely 2019 could be ready to see a jump in deals. According to a report* from McKinsey & Company, the number of healthcare services deals among institutional investors nearly doubled from 2012 to 2017.
- GlobeNewswire•last month
Tonix Pharmaceuticals Announces Innovative Design in Next Phase 3 Study of Tonmya® for PTSD, Following FDA Meeting
Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company), today announced that it plans to start a new Phase 3 trial of Tonmya®* for the treatment of posttraumatic stress disorder (PTSD) in the first quarter of 2019, based on guidance from its recent Breakthrough Therapy Type B Clinical Guidance meeting with the U.S. Food and Drug Administration (FDA). Tonix submitted interim analysis results from the original Phase 3 HONOR study of Tonmya in military-related PTSD to support a new Phase 3 study design discussion with the FDA.
- GlobeNewswire•last month
Tonix Pharmaceuticals will Present Phase 3 HONOR and Phase 2 AtEase Study Results in Poster Presentations at CNS Summit 2018
NEW YORK, Oct. 29, 2018 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) announced today that it will be presenting findings and retrospective analyses from the.
- ACCESSWIRE•2 months ago
Today’s Research Reports on Stocks to Watch: Tonix Pharmaceuticals and Vital Therapies
NEW YORK, NY / ACCESSWIRE / October 4, 2018 / Tonix Pharmaceuticals and Vital Therapies Inc. both saw big gains in Wednesday’s session despite either company releasing any news nor there being any catalyst to set shares off. Tonix was expected to have presented this week at the MicroCap Conference. Tonix Pharmaceuticals Holding Corp. shares closed up 17.80% on Wednesday with an additional gain of 5.04% in after-hours trading.
- GlobeNewswire•2 months ago
Tonix Pharmaceuticals to Present at the MicroCap Conference
Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present and host investor meetings at the MicroCap Conference being held October 1-2, 2018, in New York City. A live webcast and subsequent archived recording of the presentation will be available under the Presentations & Events tab of the Investors section of the Tonix Pharmaceuticals website at www.tonixpharma.com.
- GlobeNewswire•3 months ago
Tonix Pharmaceuticals to Present at Sidoti & Company Fall 2018 Investor Conference
NEW YORK, Sept. 20, 2018-- Tonix Pharmaceuticals Holding Corp. announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present and host investor meetings at the Sidoti ...
- Zacks Small Cap Research•3 months ago
TNXP: Retrospective Analyses from HONOR and AtEase Trials Presented…
On August 21, 2018, Tonix Pharmaceuticals Holding Corp. (TNXP) announced a poster presentation at the 2018 Military Health System Research Symposium that included results from the Phase 3 HONOR trial and retrospective analyses from the HONOR trial and the Phase 2 AtEase trial of TNX-102 SL (cyclobenzaprine HCl sublingual tablet) in patients with posttraumatic stress disorder (PTSD). In July 2018, the company announced that the HONOR trial was stopped early due to a lack of separation between the placebo group and treated group at the 12-week timepoint.
- Benzinga•4 months ago
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! SPDR S&P Retail (NYSE: XRT ) could see increased volatility ...
